#+OPTIONS: tex:t
* Wang /pharmacology
** [#A] class → ion channel target
*** 1a
Na fast channel block; prolonging action potential
*** 1b
Na; shorten action potential
*** 1c
- Na; doesn’t prolong APD or QT interval
- supraventricular arrhythmias
*** 2
β blockers; prolong AP
*** 3
K
**** effects
- ↑ APD
- ↑ QT
- ↑ refractory periods
*** 4
Ca
** [#B] drug → ion channel
*** lidocaine
inhibits sodium current
*** amiodarone
- inhibits I_Na, I_Ca, I_Kr, I_Ks
- ↑ APD
- ↑ QT interval
*** verapamil
lCa
** [#A] drug → classification
*** diltiazem
class 4 CCB
*** lidocaine
subgroup 1B
*** dronedarone
class 3; prolongs refractory peroid
*** metoprolol
class 2 β-blocker
*** name some other antiarrhythmic drugs
- adenosine
- digoxin
** [#C] drugs that can’t prolong APD or QT interval
- flecainide
- propafenone
** [#C] lidocaine’s use-dependent effect
- doesn’t affect healthy tissue
- rapid kinetics selectively depresses conduction in depolarized, diseased cells
** [#C] amiodarone adverse drug reactions 
- blindness
- thyroid
- pulmonary fibrosis
- Torsades de pointes
** [#B] digoxin
*** mechanism of action
- parasymathomimetic effects
- good for AF
- pro-arrhythmic otherwise because it increases sympathetic outflow
*** adverse drug reactions
- digitalis-induced bigeminy; DAD
- ventricular fibrillation (VF)
*** [#A] why digoxin is pro-arrhythmic
- sympathetic outflow increased at toxic levels
- [Ca]_i overload
*** [#B] positive ionotropic effect of digoxin
- ↑ [Ca]_i
- ↑ [Na]_i
- ⇥ Na-K-ATPase
- ↑ NCX
- ↑ contractility
** [#C] similarity of ibutilide and amiodarone
I_Kr
** [#C] dobutamine
*** mechanism of action 
- positive inotropic effect
- selective β-1 agonist
*** signaling pathway
1. β-agonism
2. ↑ PKA
3. phosphorylation of phospholamban
4. ⇥ SERCA
** Name phosphorylation targets of PKA following activation of beta receptors and/or inhibition of PDE :l:
*** RyR2
*** Ca channel protein
*** Phospholamban
1. β-agonism
2. ↑ PKA
3. phosphorylation of phospholamban
4. ⇥ SERCA
phospholamban inhibits SERCA (sarcoplasmic endoplasmic reticuluum Ca-ATPase), increasing Ca
** [#A] anemia
*** causes :l:
**** intrinsic factor
dereased B12 absorption
**** erythropoiten deficiency
**** iron deficiency
**** folate deficiency
*** difference between folate deficiency and B12 deficiency
- pernicious anemia ∈ B12 deficiency symptoms
- ↑ methylmalonic acid ∈ B12 deficiency symptoms
** chronic kidney disease
*** [#A] pathological changes
- anemia
- protein in urine
- higher PTH
- Ca
- P
- ↑ BUN
- ↓ EPO
- Vitamin D
*** [#A] vitamin D
**** metabolism in skin, liver, kidney
- kidney: 1,25-(OH)_2-D calcitriol
- liver: 25-(OH)-D calcifediol
- skin: cholecalciferol
**** most active form
calcitriol > calcifediol >> cholecalciferol
** [#B] respiratory
*** mechanism of actions
**** SABA
β-2 agonism then cAMP signaling
**** LABA
β-2
**** SAMA
competitive inhibitors for acetylcholine at M_1, M_3
**** LAMA
competitive inhibitors for acetylcholine at M_1, M_3
**** Roflumilast
PDE4 inhibition
**** steroids
⇥ arachidonic acid synthesis; thus blocking COX_2 and prostaglandin synthesis
*** compare the anti-inflammatory effects of steroids, 5-lipoxygenase inhibitors, leukotriene receptor antagonists and PDE inhibitors
- steroids inhibit arachidonic acid synthesis
- 5-lipoxygenase inhibitors
- LTD4 antagonists directly block end receptor
- PDE inhibitors keep cAMP around to bronchodilate
* arrhythmias
** Lisi
*** CHA²DS²-VASc Score²
- Congestive heart failure: 1 point
- HTN: 1
- age ≥75: 2
- age 65-74: 1
- diabetes: 1
- prior stroke/TIA/TE: 2
- vascular disease: 1
- female: 1
**** treatment guidelines
- 0: nothing
- 1: aspirin, anticoagulant, or nothing
- >2: need anticoagulation (/not/ Plavix): warfarin, epixaban, edoxaban, rivaroxaban
*** treatment
**** TODO anticoagulants with doses
**** rate control vs. rhythm control
***** ejection fraction <40%
no DHP ccalcium channel blockers
***** TODO summary slide
*** torsades de points (TdP)
**** risk factors
- female
- renal compromise
- electrolyte disorders
**** drugs
- fluoroquinolones
- SSRIs
- ibuprofen
*** digoxin toxicity, risk factors
- renal compromise; digoxin is renally cleared
- advanced age
- electrolyte disorders
  - K
  - Mg
  - P
  - Na
* Samuel
** COPD
*** [#B] vs. asthma
- hyperinflation and decreased recoil
- steroids are useful
- neutrophils
- reversible
- CD8, neutrophils, macrophages
*** GOLD
1. FEV >80
2. (50, 80)
3. (30, 50)
4. (0, 30)
*** [#B] drugs :l:
**** β-2 agonists
- albuterol
- levalbuterol
- albuterol
**** SAMA
- ipratropium bromide
**** SABA/SAMA combinations :l:
***** albuterol/ipratropium
****** [#B] brand
- Combivent Respimat
- DuoNeb
**** LABA
**** ICS combinations :l:
***** salmeterol/fluticasone
****** [#A] brand
Advair
***** formoterol/budenoside
****** [#A] brand
Symbicort HFA
**** methylxanthines
- Roflumilast
- Theophylline
*** [#A] by category
- A) {SABA, SAMA, LABA, LAMA}
- B) {LABA, LAMA}
- C) LAMA
- D) {LABA + LAMA, LABA + ICS}
*** patient care plan for smoker
- PPSV13, PPSV23 1yr
- Ask, Advise, Assess, Assist, Arrange
- macrolides, doxycycline, Augmentin
** anemia
*** ESAs
- darbapoetin
- epotein
- BBW: cardiovascular
*** [#C] IV iron formulations :l:
**** ferric gluconate
***** brand
Ferrlecit
**** iron dextran
***** brand
Infed
**** iron sucrose
***** brand
Venofer
**** ferumoxytol
***** brand
Feraheme
**** ferric carboxaltose
***** brand
Injectafer
* [#B] Mody / medicinal chemistry
** [#A] lidocaine
- lidocaine must be given by IV; trisubstituted amino group leads to rapid and efficient first-pass metabolism
- tocainide is the orally active alternative because its amino group is unsubstituted
** sleep
*** melatonin
**** [#B] disadvantages
- poor absorption
- low oral bio-availability
- ubiquitious effects
**** ramelteon
analog of melatonin for long-term insomnia; non-scheduled
***** [#A] brand
Rozerem
*** benzodiazepines
**** mechanism of action
GABA_A modulators at α-1 and γ-2 subunits
**** 2-keto benzos
- long half lives; 60 hrs
- active metabolites
**** triazolo benzos
**** 3-hydroxy benzos
no active metabolites
*** barbituate
**** mechanism of action
GABA_A at α-1 subunit
*** zolpidem/zaleplon/eszopiclone
**** mechanism of action
GABA_A at α-1 only
**** zolpidem (Sonata)
- pKa=6.2; weak base
- 1.5h half life
*** flumazenil
**** mechanism of action
- selective GABA_A antagonist
- blocks zolpidem/zaleplon/eszopiclone
- doesn’t block barbituates, meprobamate, or ethanol
*** [#A] structure → drug
**** <img src="https://upload.wikimedia.org/wikipedia/commons/thumb/4/4b/Benzodiazepine_a.svg/1200px-Benzodiazepine_a.svg.png"/>
benzodiazepine
**** <img src="https://upload.wikimedia.org/wikipedia/commons/thumb/2/24/Zaleplon_Structural_Formulae_V.1.svg/220px-Zaleplon_Structural_Formulae_V.1.svg.png"/>
zaleplon
**** <img src="https://upload.wikimedia.org/wikipedia/commons/thumb/3/3e/Eszopiclone.svg/1200px-Eszopiclone.svg.png"/>
eszopiclone
**** <img src="https://upload.wikimedia.org/wikipedia/commons/thumb/b/b0/Zolpidem.svg/1200px-Zolpidem.svg.png"/>
zolpidem
**** <img src="https://upload.wikimedia.org/wikipedia/commons/thumb/0/03/Buspirone_200.svg/1200px-Buspirone_200.svg.png"/>
buspirone
**** <img src="https://upload.wikimedia.org/wikipedia/commons/thumb/0/0d/Ramelteon_skeletal_formula.svg/1200px-Ramelteon_skeletal_formula.svg.png"/>
ramelteon
**** <img src="https://upload.wikimedia.org/wikipedia/commons/thumb/c/ca/Flurazepam.svg/1200px-Flurazepam.svg.png"/>
a 2-keto benzodiazepine (flurazepam)
**** <img src="https://upload.wikimedia.org/wikipedia/commons/thumb/2/24/Lorazepam.svg/1200px-Lorazepam.svg.png"/>
a 3-hydroxy benzodiazepine (lorazepam)
**** <img src="https://upload.wikimedia.org/wikipedia/commons/thumb/3/31/Alprazolam_structure.svg/1200px-Alprazolam_structure.svg.png"/>
a triazolo benzodiazepine (alprazolam)
** hypnotics and seizures
*** [#A] structure → drug
**** <img src="https://upload.wikimedia.org/wikipedia/commons/thumb/b/b4/Iprodione.png/220px-Iprodione.png"/>
hydantoin
**** <img src="https://upload.wikimedia.org/wikipedia/commons/thumb/4/49/Barbituric-acid-structural.svg/1200px-Barbituric-acid-structural.svg.png"/>
barbituate
**** <img src="http://www.prepchem.com/wp-content/uploads/2016/01/Synthesis-of-succinimide.png"/>
succinimide
**** <img src="https://www.sigmaaldrich.com/content/dam/sigma-aldrich/structure1/114/mfcd00005268.eps/_jcr_content/renditions/mfcd00005268-medium.png"/>
oxazolidinone
**** <img src="https://upload.wikimedia.org/wikipedia/commons/thumb/8/87/Dibenzazepine.png/1200px-Dibenzazepine.png"/>
dibenzazepines
**** <img src="https://upload.wikimedia.org/wikipedia/commons/thumb/b/ba/Acetazolamide.svg/1200px-Acetazolamide.svg.png"/>
acetazolamide
**** <img src="https://upload.wikimedia.org/wikipedia/commons/thumb/a/a6/Gabapentin2DACS.svg/1200px-Gabapentin2DACS.svg.png"/>
gabapentin
**** <img src="https://upload.wikimedia.org/wikipedia/commons/thumb/d/df/Pregabalin_Structural_Formulae.png/259px-Pregabalin_Structural_Formulae.png"/>
pregabalin
**** <img src="https://upload.wikimedia.org/wikipedia/commons/thumb/0/04/Vigabatrin2DCSD.svg/1200px-Vigabatrin2DCSD.svg.png"/>
vigabatrin
**** <img src="https://upload.wikimedia.org/wikipedia/commons/thumb/2/24/Tiagabine.svg/1200px-Tiagabine.svg.png"/>
tiagabine
* heart failure
** TODO NYHA functional classification
** TODO drugs reducing mortality in heart failure
- metoprolol
** drugs symptom control
- furosemide
- digoxin
** TODO [#A] subset of heart failure exacerbation, treatment
*** TODO [#A] acute decompensated heart failure
* renal
** causes
* fluid and electrolytes
** crystalloid fluids
** TODO fluid distribution
** TODO treatment
*** sodium disorders
*** potassium disorders
* acid base disorder
** TODO identify acid base disorder based on lab values
** TODO appropriate management of 4 types of acid base disorders
* pulmonary hypertension
** TODO treatment based on vasoreactivity test
** TODO pregnancy
* cystic fibrosis
** TODO [#A] targeted on CFTR protien
idocaftrer???
leumocafter?
** [#A] pulmonary toilet
- albuterol to open up airways
- dornate alpha
- hypertonic saline
- inhaled antibiotics for Pseudomonas
** [#A] exacerbation of CF
- multi-drug resistant Pseudomonas
- double cover because of drug resistance
* sleep disorders
** definition
changes in the normal sleep cycle that can negatively affect your health
*** primary
not attributable to any other condition
*** secondary
attributable to an identifiable cause---e.g., medication or disease state
*** dyssomia
Dyssomnias are a broad classification of sleeping disorders involving difficulty getting to sleep, remaining asleep, or of excessive sleepiness.
*** parasomnia
Parasomnias are a category of sleep disorders that involve abnormal movements, behaviors, emotions, perceptions, and dreams that occur while falling asleep, sleeping, between sleep stages, or during arousal from sleep. Most parasomnias are dissociated sleep states which are partial arousals during the transitions between wakefulness and NREM sleep, or wakefulness and REM sleep.
** GABA neuropharmacology
*** GABA role
inhibitory neurotransmitter
*** GABAergic receptors
**** GABA_A
- Have chloride channels associated with in the receptor
- Modulated by GABA, Benzodiazepines, Barbiturates
***** agonists
****** drugs
- benzodiazepines
- zolpidem, zaleplon, eszopiclone
****** pharmacology
- enhances membrane hyperpolarization similar to benzodiazepines
- doesn’t cause anxiolysis, muscle relaxation, or amnesia
***** [#A] antagonists
flumazenil
**** GABA_B
***** [#A] agonists
Baclofen
** epidemiology
- African Americans
- Elderly
** sleep
*** cycles
**** NREM
nonrapid eye movement---75% of the time
***** stage 1
- sleep is initiated
- relaxed wakefulness
***** stage 2
- alpha wave sleep
- preparation for deep sleep
- muscles and brain are relaxed
***** stage 3 & 4
- slow wave delta sleep
- deep sleep
- body is healing itself
**** REM
- rapid eye movement---20-30% of the time
- brain is more active
- Lateral eye movement 
- Heart rate increases
- Respiration increases
- Increased cerebral blood flow
- Muscle atonia
- Varying body temperature
- Dreaming 
*** regulation of sleep
**** neurotransmitters
- H
- DA
- NE
- 5HT
- ACh
**** suprachiasmatic nucleus
controls the release of the neurotransmitters 
** insomnia
*** first line
- Short acting BZD or BzRA or ramelteon
- if comorbid depression/anxiety: sedating antidepressant or combination with BzRa or ramelteon
*** drug classes :l:
**** benzodiazepines
***** drugs :l:
****** Alprazolam
******* brand
Xanax
****** Chlordiazepoxide 
******* brand
Librium
****** Clorazepate 
******* [#B] brand
Tranxene
******* [#B] indication
partial seizures; in combination with other drugs
******* [#A] mechanism of action
active metabolite, desmethyl-diazepam, is a partial agonist of GABA_A
****** Clonazepam 
******* brand
Klonopin
****** Diazepam 
******* brand
Valium
****** Estazolam 
******* brand
ProSom
****** Flurazepam 
******* brand
Dalmene
****** Lorazepam 
******* brand
Ativan
****** Midazolam 
******* brand
Versed
****** Quazepam 
******* brand
Doral
****** Temazepam 
******* brand
Restoril
****** Triazolam 
******* brand
Halcion
***** interactions
****** severe liver impairment
- oxazepam
- temazepam
- lorazepam
***** drugs by duration of action
****** [#A] ultrashort acting drugs 6h
- triazolam
- midazolam
****** [#B] long acting drugs (24-48h)
- diazepam
- chlordiazepoxide
- flurazepam
- clonazepam
- clorazepate
**** barbituates :l:
***** Amobarbital 
****** brand
Amytal
***** Mephobarbital 
****** brand
Mebaral
***** Pentobarbital 
****** brand
Nembutal
***** Phenobarbital 
****** brand
Luminal
***** Secobarbital 
****** brand
Seconal
**** GABA_A agonists aka “Z Hypnotics” :l:
***** Eszopiclone 
****** brand
Lunesta
****** indication
effective for maintaining sleep---secondary to longer duration
***** Zaleplon 
****** brand
Sonata
***** Zolpidem 
****** brand
Ambien
**** Melatonin receptor agonists :l:
***** Ramelteon 
****** brand
Rozerem
****** [#A] MOA
M1 and M2 receptor antagonist
****** adverse effects
- worsening depression
- psychosis
**** 5-HT1A-partial agonist :l:
***** Buspirone 
****** brand
BuSpar
****** [#A] MOA
- partial agonist at 5-HT_1A receptors
- ↓ 5HT activity
- ↑ NA and DA activity
- requires repeated administration
****** difference with benzodiazepines
- no action on GABA_A sites
- no interaction with the GABAergic system
- elderly are /not/ more sensitive to buspirone
- not a controlled substance
**** orexin receptor antagonist :l:
***** suvorexant
****** brand
Belsomra
****** MOA
orexin (hypocretin) is released from the hypothalamus to promote wakefulness or arousal
**** sedating antipsychotics :l:
***** olanzapinep
****** brand
Zyprexa
***** quetiapine
****** brand
Seroquel
**** antidepressants :l:
***** doxepin
****** brand
Silenor
***** amitryptiline
***** mirtazapine
***** trazodone
*** consequences
** obstructive sleep apnea
*** diagnosis
polysomnography; 5-15+ events/hr
*** non-pharmacologic
Positive Airway Pressure is the gold standard
*** pharmacologic
**** drugs :l:
***** modafinil (Provigil)
***** armodafinil (Nuvigil)
**** indication
Residual excessive daytime sleepiness despite effective PAP treatment
** narcolepsy
*** first line :l:
**** modafinil 200mg qAM, max 400mg/day
**** armodafinil 150-250 mg qAM
*** tetrad :l:
**** cataplexy
- abrupt loss of muscle tone
- narcolepsy + cataplexy is the most common
- Cataplexy is a sudden and transient episode of muscle weakness accompanied by full conscious awareness, typically triggered by emotions such as laughing, crying, or terror.[1] Cataplexy affects approximately 70% of people who have narcolepsy,[2] and is caused by an autoimmune destruction of neurons that produce the neuropeptide hypocretin (also called orexin), which regulates arousal and wakefulness. Cataplexy without narcolepsy is rare and the cause is unknown.
***** first line
sodium oxybate (GHB) 2.25-4 g/HS (powder); repeat dose in 4 hoursp
**** EDS
Uncontrollable excessive daytime sleepiness (EDS)
**** paralysis
**** hallucinations
** circadian rhythm disorders
*** jet lag
**** pharmacologic
- melatonin prior to the trip
- benzodiazepines, short-acting
*** restless leg syndrome
**** causes
low dopamine; treatment is dopamine agonists
**** drugs
***** dopamine agonists :l:
****** Ropinirole
******* brand
Requip
****** Pramiprexole
******* brand
Miraxpex 
****** Levodopa/Carbidopa
******* brand
Sinemet
****** Rotigotine 
***** anticonvulsants :l:
****** Gabapentin Enacarbil
******* brand
Horizant
****** Gabapentin
******* brand
Neurontin 
****** Pregabalin
******* brand
Lyrica 
**** first line
dopamine agonists
*** shift work sleep disorder
**** pharmacologic
- melatonin
- benzodiazepines
- modafinil or armodafinil
*** (Non-24) Non-24 hour sleep wake disorder
If you have Non-24-hour sleep-wake disorder (Non-24), you may find yourself gradually going to bed later every night and waking up later each day. Eventually, your sleep schedule goes all the way around the clock. Common in the legally blind.
**** non-pharmacologic
- Sleep schedule
- Bright light therapy (sight)
**** pharmacologic :l:
***** tasimelteon
****** dosing
20 mg/HS
****** brand
Hetlioz
***** melatonin
****** structure
[[./melatonin.png]]
** name → structure
*** melatonin
[[./melatonin.png]]
* epilepsy
** neuropharmacology
*** [#A] glutaminergic receptors
- N-methyl-D-aspartate (NMDA Receptors)
- AMPA (alpha-amino-3-hydroxymethyl-4-isoxazolepropionic acid) Receptors
- Kainate Receptors
** causes
- neurologic diseases
- heredity
- gene defects
** classes
*** partial seizures :l:
**** simple partial
preservation of consciousness
**** complex partiali
mpaired consciousness lasting 30 seconds - 2 minutes
**** partial with secondarily generalized tonic-clonic seizure
- simple or complex partial seizure with loss of consciousness and tonicity (sustained contractions) followed by periods of clonicity (relaxation)
- typically lasts 1-2 minutes
*** generalized seizures :l:
**** Generalized tonic-clonic (grand mal) seizures
**** Absence (petit mal) seizures
abrupt onset of impaired consciousness; e.g., staring off into the void for 30 seconds
**** myoclonic seizure
A brief (perhaps a second), shock like contraction of muscles that may be restricted to part of one extremity or may be generalized
**** Tonic seizures
**** Atonic seizures
**** Clonic and myoclonic seizures
**** Infantile spasm
** indication → drugs
*** [#A] status epilepticus
- lorazepam 4mg IV repeat in 15 min
- diazepam
** structure → name
*** [[./azapane_azapine.png]]
azapane	diazapine
*** [[./benzodiazepines.png]]
benzodiazepines
*** [[./ureides.png]]
ureides
*** [[./sulfonamides.png]]
sulfonamides
*** [[./dibenzapine.png]]
dibenzapines
** therapeutics
*** reasons to beign pharmacologic treatment
- after 2nd unprovoeked seizure
- after 1st seizure & risk factors for 2nd seizure
- 2nd seizure ocurrence produces large consequences
  - elderly patients
  - psychosocial consequences
*** medications that lower seizure threshold
*** TODO broad spectrum
*** TODO narrow spectrum
Phenytoin
Valproic Acid
Phenobarbital
Lamotrigine
Carbamazepine
Topiramate
Oxcarbamazepine
Zoniesamide
Gabapentin
Levetiracetam
Pregabilin
Clonazepam
Lacosamide
Rufinamide
Vigabatrin
*** drug interactions
**** inducers
- Carbamazepine (potent)
- Phenytoin (potent)/Fosphenytoin
- Phenobarbital/Primidone (potent)
- Topiramate > 200 mg/day
- Felbamate 
**** inhibitors
- Dilvaproex sodium/Valproic Acid
- Topiramate
- Felbamate 
*** adverse effects
**** ocurrence
can happen when dose is titrated up quickly or in large increments---or even in normal dosage ranges
*** special populations
**** elderly
- lower doses
- monotherapy
**** pregnant
- avoid teratogens: depakote, valproic acid, carbamazepine
- supplement with folic acid 0.4-5 mg/day
- most AEDs will pass through breast milk
**** children
higher dose
** drug classes
*** newer agents
**** Voltage gated calcium channels :l:
***** Gabapentin
****** [#A] MOA
Bind selectively to high affinity to Ca2+ channel subunit α2δ-1 protein in cortical membrane
****** pharmacokinetics
- renally eliinated; requires dose adjustments
****** indication
comorbid neuropathic pain
****** clinical considerations
few drug interactions
***** Pregablin
****** MOA
Bind selectively to high affinity to Ca2+ channel subunit α2δ-1 protein in cortical membrane
****** adverse effects
****** indication
- comorbid anxiety
- neuropathic pain
****** compared to gabapentin
- more potent
- less GI adverse drug reactions
- used for comorbid neuropathic pain, not just seizures
**** GABA uptake/GABA-T inhibitor :l:
***** Tiagabine
****** [#A] mechanism of action
⇥ GAT-1
***** Vigabatrin
****** [#B] mnemonic
- gabat...GABA T...GABA transaminase
- VInyl GABA TRansaminase INhibitor
****** [#A] MOA
GABA-T inhibitor
****** adverse effects
irreversible vision loss
**** NMDA antagonist :l:
***** Felbamate
****** adverse drug reactions
- aplastic anemia
- hepatic failure
**** AMPA/Kainate receptor antagonist :l:
***** Topiramate
****** adverse effects
dose-related cognitive impairment; difficulty in stringing together sentences
***** Perampanel
****** black box warning
Serious life threatening psychiatric & behavioral reactions
**** HCN channel activity enhancer :l:
***** Lamotrigine
****** [#A] mechanism of action
delays recovery from inactivation of recombinant Na+ channels
****** [#A] elimination
95% excreted in urine
****** indication
- partial and secondarily generalized tonic-clonic seizures in adults
- Lennox-Gastaut syndrome in both children and adults 
****** adverse effects
rash which may progress to SJS
****** [#B] dosing
25 mg Daily, titrated by 25 mg to a max of 200 – 400 mg. Dependent on dosing with inhibitors or inducers.
****** warnings
Hemophagocytic Lymphohistiocyosis (HLH)
****** brand
Lamictal
**** SV2A protein ligand
Levitiracetam
**** Ca and Na channels blocker :l:
***** Zonisamide
use cautiously in sulfa allergies
**** Voltage Gated Na Channels :l:
***** Lacosamide
****** brand
Vimpat
****** indication
partial-onset seizures; refractory partial seizures
****** MOA
Lacosamide enhances slow inactivation of voltage-gated Na+ channels and limits sustained repetitive firing, the neuronal firing pattern characteristic of partial seizures
****** adverse effects
- increases PR interval
****** clinical considerations
- 2nd line secondary to cost
**** Carbonic anhydrase inhibitor :l:
***** Acetazolamide
****** brand
Diamox
****** indication
absence seizures
****** [#B] chemical identity
- sulfonamide
- thiadiazole
****** mechanism of action
inhibition of carbonic anhydrase; retards abnormal firing of neurons in the brain
***** Zonisamide
****** brand
Zonegran
**** cannabinoids :l:
***** cannabidiol
****** brand
Epidiolex
****** indication
- Lennox-Gastaut Syndrome
- Dravet Syndrome 
**** other
***** Rufinamide
****** indication
used in Lenox-Gastaut syndrome
*** older agents :l:
**** Hydantoins
***** drugs :l:
****** phenytoin
******* [#A] brand
Dilantin
******* [#B] therapeutic concentration
10-20
******* pharmacokinetics
- nonlinear
- 90% protein bound; when albumin levels fall, concentration increases
******* [#A] solubility
- poorly water soluble as free base; pKa=8
- must be infused IV as sodium salt; pKa=11
******* [#A] prodrug
fosphenytoin---phosphate ester of phenytoin:
- water soluble
- IV compatible
******* [#A] adjusted total phenytoin concentration
\begin{equation}
[Phenytoin]_\text{adj} = \frac{[Phenytoin]_\text{obs}}{0.2*Albumin + 0.1}
\end{equation}

\begin{equation}
[Phenytoin]_\text{adj} = \frac{[Phenytoin]_\text{obs}}{0.9 * \frac{Albumin}{Albumin_\text{normal}} + 0.1}
\end{equation}
******* MOA
- Limits the repetitive firing of action potentials evoked by a sustained depolarization
- Selectively, slows the rate of recovery of voltage-activated Na+ channels from inactivation, an action that is both voltage- and use-dependent (without affecting GABA or glutamate) 
- Blocks high-frequency firing of neurons through inhibitory actions on VG-Na+ channels
******* interactions
Valproate competes for protein binding sites and inhibits phenytoin metabolism, resulting in marked and sustained increases in free phenytoin
******* [#A] adverse drug reactions
- gingival hyperplasia
- hirsuitism
- inhibits insulin---hyperglycemia, glycosuria
- megaloblastic anemia
- ↓ IgA
- vitamin D; osteomalacia, hypocalcemia
- alkaline phosphate; hypersensitivity
- neutropenia/leukopenia
******* indications
- cardiac arrhythmia
- partial seizures
- tonic-clonic seizures
******* non-indications
absence seizures
******* monitoring
- 10-20 mcg/mL
- CBC
- LFTs
- bone density
****** phosphenytoin
****** mephenytoin
****** ethotoin
***** structure
[[./hydantoins.png]]
**** Benzodiazepines
***** [#A] MOA
- increases chloride flux
- at therapeutically relevant concentrations: act at subsets of GABA_A receptors and increase the frequency, but not duration, of openings at GABA-activated chloride channels
- at higher concentrations: diazepam and other benzodiazepines reduce sustained high-frequency firing of neurons, similar to the effects of phenytoin, carbamazepine, and valproate
***** [#B] adverse effects
- sedation
- anterograde amnesia
- hypnosis
- anaesthesia
***** effect on sleep/hypnotic patterns

***** structure
[[./benzodiazepines.png]]
***** drugs :l:
****** clonazepam
******* brand
Klonopin
****** clorazepate
******* brand
Tranxene
****** diazepam
******* brand
Valium
******* indication
status epilepticus
****** lorazepam
******* brand
Ativan
******* indication
status epilepticus
***** interactions
CYP3A4
**** Barbiturates :l:
***** Phenobarbital
Relatively low toxicity, is inexpensive, and is still one of the more effective and widely used drugs for control of generalized tonic-clonic and partial seizures
****** indication
generalized tonic-clonic and partial seizures
****** nonindications
abscence seizures
****** MOA
Potentiation of GABA_A receptor-mediated synaptic inhibition
****** adverse effects
- CNS depression/sedation
- sedative effect that disturbs behavior in children
****** pharmacokinetics
potent inducer
**** Iminostilbenes :l:
***** Carbamazepine
****** MOA
- Selectively, slows the rate of recovery of voltage-activated Na+ channels from inactivation 
- Limits the repetitive firing of action potentials evoked by a sustained depolarization of mouse spinal cord or cortical neurons maintained in 
- Carbamazepine metabolite, 10,11-epoxycarbamazepine, also limits sustained repetitive firing at therapeutically relevant concentrations
****** metabolism
metabolite also limits sustained repetitive firing at therapeutically relevant concentrations
****** indication
- trigeminal and glossopharyngeal neuralgias
- generalized tonic clonic
- simple and complex partial seizures
****** [#B] pharmacokinetics
- autoinducer
- induces enzyme that metabolizes itself, CYP3A4
****** [#A] difference with older classes of antiseizure medications
less sedating effect
***** Oxcarbazepine
****** indication
- partial seizures
****** adverse effects
hyponetremia
****** [#A] advantages over carbamazepine
- ketone moiety protects from metabolized by oxiation
- oxcarbamazepine is a less potent inducer than carbamazepine
****** prodrug?
- not a prodrug of carbamazepine
- prodrug of azocarbazepine
***** Eslicarbazepine
****** dosing
400 mg/day, max 1200 mg/day, /once daily/
**** Succinimides :l:
***** Ethosuximide
****** [#B] indication
- /only/ absence seizures
- narrow spectrum
****** mechanism of action
↓ low threshold Ca currents (T-type)
****** TODO adverse drug reactions
**** valproic acid
***** [#A] mechanism of action
- ⇥ GABA-T
- ⇥ succinic semialdehyde dehydrogenase
***** indication
broad spectrum:
- absence
- partial seizures
- generalized tonic-clonic seizures
- myoclonic
***** adverse effects
- hepatotoxicity
- thrombocytopenia
- increased NH_4
***** pharmacokinetics
highly protein bound
*** [#A] structurally related to GABA
- vigabatrin
- gabapentin
- pregabalin
- tiagabine
** status epilepticus
- consecutive seizures lasting 5+ minutes or continuously
- longer the seizure, the worse it is for mortality/morbidity
*** [#B] treatment
**** emergent initial therapy
benzodiazepines; lorazepam IV 4mg IV repeat 10-15 min.
Goal is to /stop/ the seizure.
**** [#A] urgent control therapy
- phenytoin 10-20 mg/kg may repeat in 10 min
- 75 mg fosphenytoin ≍ 50 mg phenytoin
ideally, you don’t want to have to titrate up.
Goal is to prevent further seizure.
**** treatment refractory
Goal is to /stop/ the seizure.
- continuous infusion of AED + bolus doses of AED to prevent breakthrough seizures
- medically induced coma
*** nonpharmacologic treatment
- metabolic acidosis: sodium bicarbonate
- respiratory acidosis: ventilation
- hypoglycemia: glucose
- alcoholics/Wernicke encephalopathy: thiamine before glucose
** TODO role of voltage gated sodium channels in epilepsy
** TODO metabotropic G-protein receptors
** TODO listen to 9:00am-9:15am Sharma 2018 Feb 6
* asthma
** increments of drug therapies
1. SABA PRN
2. low-dose ICS
3. {medium-dose ICS, low-dose ICS and LABA}
4. medium-dose ICS + LABA
5. high-dose ICS + LABA
6. high dose ICS + LABA + oral corticosteroid
** Interleukin-5 (IL-5) receptor antagonist agents :l:
*** Mepolizumab
**** brand
Nucala
*** Reslizumab
**** brand
Cinqair
*** Benralizumab
**** brand
Fasenra
** anti-IgE :l:
*** Omalizumab
**** brand
Xolair
** inhaled short-acting β-2 agonists (SABA) :l:
*** albuterol
**** MDI
***** brand
- ProAir HFA
- Proventil HFA
**** DPI
***** brand
- ProAir Respiclick
** inhaled long acting β-2 agonists (LABA) :l:
*** salmeterol
**** brand
Serevent Diskus
*** formoterol
*** vilanterol
** ICS+LABA combinations :l:
*** fluticasone/salmeterol
**** brand
- Advair {Diskus, HFA}
- AirDuo Respiclick
*** mometasone/formoterol
**** brand
Dulera MDI
*** budenoside/formoterol
**** brand
Symbicort MDI
*** fluticasone furoate/vilatnerol
**** brand
Breo Ellipta DPI
** inhaled corticosteroids :l:
*** beclomethasone
**** brand
QVAR (RediHaler)?
*** budenoside
**** brand
Plumicort {Respules [nebulizer], Flexhaler [DPI]}
*** ciclesonide
**** brand
Alvesco
*** fluticasone propionate
**** brand :l:
***** Flovent HFA
- BID
- doses low to high: 176..440
***** Flovent Diskus
- BID
- doses low to high: 200..500 mcg
***** Arnuity Ellipta
- ONCE DAILY
- doses low to high: 100 mcg..200 mcg
*** mometasone
**** brand
Asmanex {HFA, Twisthaler}
* COPD
* cystic fibrosis
** [#A] genetic inheritance
- autosomal recessive
- CFTR gene
** [#B] organs affected
- pulmonary
- pancreas
- intestines
- liver
- sweat glands
- reproductive
** [#B] s/s
- bacterial growth in lungs
- ↓ FEV1
** [#A] diagnostic criteria
- sweat chloride test ≥ 60; uses pilocarpine
- newborn screening
** [#A] treatment steps
1. albuterol
2. hypertonic saline
3. dornase alfa (Pulmozyme)---mucolytic DNA cleaver
4. percussion
5. inhaled antibiotics---tobramycin (Tobi), aztreonam (Cayston)---to target Pseudomonas
** [#B] future therapies
gene therapies:
- Ivacaftor (Kalydeco)
- Lumacaftor and Ivacaftor (Orkambi)
** [#A] pulmonary exacerbations
- IV antibiotics
- Pseudomonas overage with double coverage
  - gentamicin (once daily)
  - tobramycin (once daily)
  - amikacin (once daily)
- higher doses than average population because rapid metabolizers

